ArticleCardiovascular diabetology. Endocrinology reports2026
Prevalence and association of metabolic syndrome components with benign prostate hyperplasia.
Article in Cardiovascular diabetology. Endocrinology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBenign prostate hyperplasia (BPH) is a non-cancerous enlargement of both glandular and epithelial tissue of the prostate. The disease affects a significant portion of older ages, particularly those above 40 years old. It is thought that in addition to age, there is a contribution of metabolic syndrome (Mets) to the pathogenesis of BPH. There is scanty of study regarding to association of MetS with BPH, So this study is primarily intended to assess the association of MetS with BPH among patients attending Jimma University Medical Center (JUMC). METHODS AND MATERIALS: A hospital-based cross-sectional study design was employed among 158 BPH patients attending JUMC, the subjects were selected consecutively, and all socio-demographic variables were collected by trained nurses after informed consent was obtained. Biochemical data were collected by laboratory technologists. Before analysis, daily quality control was checked. The collected data were entered into epi-data 4.6.0.6 checked, cleaned, and exported into SPSS version 26 for analysis. All descriptive variables were shown using tables, figures, and charts. After checking all assumptions of logistic regression, analysis was conducted at a significant value of 0.05.
resultsOur study found that the overall prevalence of metabolic syndrome among BPH patients was 38.6% (0.31,0.46). Among the components, low HDL comprises a high proportion following high blood glucose, elevated TG, and hyperglycemia respectively. Regarding factors associated with enlargement of the prostate, fasting blood glucose, obesity, and low HDL were significantly associated with large prostate volume (enlargement of the prostate).
conclusionAccording to our study, components of metabolic syndrome are the predictor variables for the enlargement of the prostate gland highlighting the importance of early diagnosis and treatment to alleviate further complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.